372109-22-3

Basic information

• Product Name: N-(2-(1H-indol-3-yl)ethyl)-3,5-bis(trifluoromethyl)benzamide
• Synonyms: N-(2-(1H-indol-3-yl)ethyl)-3,5-bis(trifluoromethyl)benzamide
• CAS NO: 372109-22-3
• Molecular Weight: 400.323
• Mol File: 372109-22-3.mol

Chemical Properties

• CAS DataBase Reference: N-(2-(1H-indol-3-yl)ethyl)-3,5-bis(trifluoromethyl)benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2-(1H-indol-3-yl)ethyl)-3,5-bis(trifluoromethyl)benzamide(372109-22-3)
• EPA Substance Registry System: N-(2-(1H-indol-3-yl)ethyl)-3,5-bis(trifluoromethyl)benzamide(372109-22-3)

Safety Data

• Hazardous Substances Data: 372109-22-3(Hazardous Substances Data)

Upstream product

• 61-54-1 tryptamine 
• 785-56-8 3,5-bis(trifluoromethyl)phenyl carboxylic acid chloride 

Relevant articles and documents

ADJUVANT-ANTIBIOTIC COMBINATION AGAINST GRAM-NEGATIVE BACTERIA

Tryptamine ureas and derivatives function as adjuvants to sensitize gram-negative bacteria to the effects of polymyxin antibiotics (e.g., colistin). Combination therapy of polymyxin antibiotics and the adjuvants has utility in the treatment of gram-negati

Second-Generation Tryptamine Derivatives Potently Sensitize Colistin Resistant Bacteria to Colistin

Antibiotic resistance has significantly increased since the beginning of the 21st century. Currently, the polymyxin colistin is typically viewed as the antibiotic of last resort for the treatment of multidrug resistant Gram-negative bacterial infections. However, increased colistin usage has resulted in colistin-resistant bacterial isolates becoming more common. The recent dissemination of plasmid-borne colistin resistance genes (mcr 1-8) into the human pathogen pool is further threatening to render colistin therapy ineffective. New methods to combat antibiotic resistant pathogens are needed. Herein, the utilization of a colistin-adjuvant combination that is effective against colistin-resistant bacteria is described. At 5 μM, the lead adjuvant, which is nontoxic to the bacteria alone, increases colistin efficacy 32-fold against bacteria containing the mcr-1 gene and effects a 1024-fold increase in colistin efficacy against bacteria harboring chromosomally encoded colistin resistance determinants; these combinations lower the colistin minimum inhibitory concentration (MIC) to or below clinical breakpoint levels (≤2 μg/mL).

Vinylogous acid derivatives

The invention is concerned with vinylogous acids derivatives of formula (I) wherein A and R1 to R6 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit chym